Status:
COMPLETED
Neurotropism and Neuroinflammation in COVID-19 Patients With Delirium.
Lead Sponsor:
University Hospital, Toulouse
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Covid19
Delirium
Eligibility:
All Genders
18+ years
Brief Summary
Emerging evidence indicates that SARS-CoV-2, the etiologic agent of COVID-19, can cause neurological, neuropsychological and psychiatric complications. Given the global dimensions of the current pande...
Detailed Description
The BRAINSTORM project aims at creating a proof-of-concept dataset from severe COVID-19 patients with delirium. For the first time, this longitudinal study will rely on repeated and concomitant: i) SA...
Eligibility Criteria
Inclusion
- Adult patients (male or female \> or = 18 years)
- COVID-19 (positive respiratory track PCR test \< 30 days)
- Delirium (CAM-ICU criteria)
- informed and written consent to participate in the study by patient's surrogate.
Exclusion
- medical decision of withdrawal of life sustaining treatments previous to patients recruitment
- former neurological or psychiatric disability
- MRI or PET scan contraindication
- pregnancy
- hemodynamic or respiratory failure precluding patient's transport / MRI or PET scanning
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT04785157
Start Date
June 1 2021
End Date
June 30 2022
Last Update
August 24 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Toulouse
Toulouse, France
2
CHRU Tours
Tours, France